4 completed. 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
Follow Miricorilant: new trials by email Literature Review of Miricorilant trials Research Report on Miricorilant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating the Pharmacokinetics and Safety of Miricorilant Miricorilant - Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis | Phase 1 | Completed | Corcept Therapeutics | 14 | 2026-04-30 | 2026-10-16 |
| Evaluation of Miricorilant on Liver Fat in Patients With MASLD Miricorilant - Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Phase 1 | Completed | Corcept Therapeutics | 9 | 2025-08-22 | 2026-09-30 |
| Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant Miricorilant, Fluvoxamine - Antipsychotic Induced Weight Gain, Non-alcoholic Steatohepatitis (NASH) | Phase 1 | Completed | Corcept Therapeutics | 26 | 2023-01-24 | 2023-03-22 |
| Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant Miricorilant - Non-alcoholic Steatohepatitis (NASH) | Phase 1 | Completed | Corcept Therapeutics | 19 | 2022-03-03 | 2025-03-30 |
Non-alcoholic Fatty Liver Disease (4)
United States (4)
Joseph Custodio, PhD (2) · Aprille Espinueva, PharmD (1) · Kavita Juneja, MD (1)